Antonia Dimitrakopoulou-Strauss

List of Publications by Year
in descending order

147 papers	5,627 citations	57631 44 h-index	98622 67 g-index
158 all docs	158 docs citations	158 times ranked	5560 citing authors

#	Article	IF	Citations
1	SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Molecular Imaging and Biology, 2015, 17, 313-318.	1.3	172
2	PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. Journal of Nuclear Medicine, 1991, 32, 1485-90.	2.8	169
3	Clinical Value of [18-F] Fluorodeoxyglucose Positron Emission Tomography Imaging in Soft Tissue Sarcomas. Annals of Surgery, 2000, 231, 380-386.	2.1	162
4	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 376-383.	3.3	160
5	Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. Journal of Nuclear Medicine, 1993, 34, 12-7.	2.8	144
6	Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1115-1122.	3.3	134
7	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 386-396.	3.3	130
8	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	3.3	124
9	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia, 2016, 30, 417-422.	3.3	120
10	Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 460-466.	3.3	115
11	Prognostic Significance of Preoperative [18-F] Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging in Patients With Resectable Soft Tissue Sarcomas. Annals of Surgery, 2005, 241, 286-294.	2.1	102
12	68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG. Journal of Nuclear Medicine, 2007, 48, 1245-1250.	2.8	100
13	Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. European Journal of Surgical Oncology, 2003, 29, 536-541.	0.5	98
14	Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 21-39.	3.3	96
15	Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. British Journal of Cancer, 2010, 103, 196-200.	2.9	93
16	Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. Journal of Nuclear Medicine, 2001, 42, 713-20.	2.8	92
17	The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. Journal of Nuclear Medicine, 2002, 43, 510-8.	2.8	91
18	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1289-1296.	3.3	90

#	Article	IF	Citations
19	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 175-182.	2.0	90
20	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer, 2017, 76, 60-67.	1.3	88
21	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e473-e479.	0.7	86
22	Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. Journal of Nuclear Medicine, 2001, 42, 248-56.	2.8	75
23	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <u>Ta</u>dalafil in patients with metastatic Melanoma (TaMe). OncoImmunology, 2017, 6, e1326440.	2.1	74
24	Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. Journal of Nuclear Medicine, 2004, 45, 1480-7.	2.8	67
25	Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 434-442.	2.2	66
26	Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 823-830.	3.3	64
27	Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncology, 2015, 17, 312-319.	0.6	64
28	Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nuclear Medicine and Biology, 2005, 32, 287-292.	0.3	62
29	Impact of Angiogenesis-Related Gene Expression on the Tracer Kinetics of¹⁸F-FDG in Colorectal Tumors. Journal of Nuclear Medicine, 2008, 49, 1238-1244.	2.8	59
30	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clinical and Translational Imaging, 2017, 5, 183-197.	1.1	59
31	Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging, 2012, 12, 283-289.	1.2	58
32	68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1288-1299.	3.3	58
33	Prediction of Progression-Free Survival in Patients With Multiple Myeloma Following Anthracycline-Based Chemotherapy Based on Dynamic FDG-PET. Clinical Nuclear Medicine, 2009, 34, 576-584.	0.7	57
34	PET/CT studies of multiple myeloma using 18â€‰F-FDG and 18â€‰F-NaF: comparison of distribution patterns and tracersâ€™ pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1343-1353.	3.3	55
35	18F-FDG kinetics and gene expression in giant cell tumors. Journal of Nuclear Medicine, 2004, 45, 1528-35.	2.8	55
36	Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 868-877.	3.3	53

#	Article	IF	Citations
37	Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS ONE, 2017, 12, e0183329.	1.1	53
38	Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Research, 1997, 57, 3415-23.	0.4	53
39	Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PETâ€“CT. Cancer Immunology, Immunotherapy, 2019, 68, 813-822.	2.0	51
40	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. Computational and Structural Biotechnology Journal, 2019, 17, 177-185.	1.9	51
41	Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2013, 54, 12-18.	2.8	50
42	Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. Journal of Nuclear Medicine, 1998, 39, 1197-202.	2.8	50
43	Impact of Dynamic ¹⁸F-FDG PET on the Early Prediction of Therapy Outcome in Patients with High-Risk Soft-Tissue Sarcomas After Neoadjuvant Chemotherapy: A Feasibility Study. Journal of Nuclear Medicine, 2010, 51, 551-558.	2.8	49
44	PET imaging of prostate cancer with 11C-acetate. Journal of Nuclear Medicine, 2003, 44, 556-8.	2.8	48
45	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2323-2341.	3.3	48
46	Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy, 2016, 8, 1033-1044.	1.0	47
47	Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1876-1882.	3.3	46
48	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	2.0	45
49	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	0.6	43
50	18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, e300-e307.	0.7	41
51	Clinical significance of signs of autoimmune colitis in ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy, 2019, 11, 667-676.	1.0	41
52	Shortened Acquisition Protocols for the Quantitative Assessment of the 2-Tissue-Compartment Model Using Dynamic PET/CT ¹⁸F-FDG Studies. Journal of Nuclear Medicine, 2011, 52, 379-385.	2.8	40
53	Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 704-710.	2.2	37
54	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	3.3	37

#	Article	IF	Citations
55	Multi-Path Dilated Residual Network for Nuclei Segmentation and Detection. Cells, 2019, 8, 499.	1.8	35
56	In vivoassessment of cold stimulation effects on the fat fraction of brown adipose tissue using DIXON MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 369-380.	1.9	34
57	68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 904-912.	3.3	34
58	Chemotherapeutic Management of Head and Neck Malignancies With Positron Emission Tomography. JAMA Otolaryngology, 1995, 121, 272-276.	1.5	31
59	Pharmacokinetic Imaging of¹¹C Ethanol with PET in Eight Patients with Hepatocellular Carcinomas Who Were Scheduled for Treatment with Percutaneous Ethanol Injection. Radiology, 1999, 211, 681-686.	3.6	30
60	Prediction of Short-term Survival in Patients with Advanced Nonsmall Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography: A Feasibility Study. Molecular Imaging and Biology, 2007, 9, 308-317.	1.3	30
61	Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading. Clinical Nuclear Medicine, 2011, 36, 101-108.	0.7	30
62	Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiation Oncology, 2012, 7, 157.	1.2	29
63	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Research, 2016, 6, 61.	1.1	29
64	Machine learning-based kinetic modeling: a robust and reproducible solution for quantitative analysis of dynamic PET data. Physics in Medicine and Biology, 2017, 62, 3566-3581.	1.6	29
65	The role of 18F-FLT in cancer imaging: does it really reflect proliferation?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 523-526.	3.3	28
66	Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1481-1489.	3.3	28
67	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy, 2017, 40, 282-285.	1.2	28
68	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	1.6	27
69	18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 592-602.	3.3	26
70	Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Hellenic Journal of Nuclear Medicine, 2009, 12, 223-8.	0.2	26
71	Performance evaluation of principal component analysis in dynamic FDG-PET studies of recurrent colorectal cancer. Computerized Medical Imaging and Graphics, 2003, 27, 43-51.	3.5	25
72	Correlation of the Ga-68-Bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas as Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays. Molecular Imaging and Biology, 2012, 14, 376-383.	1.3	25

#	Article	IF	Citations
73	PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin Î±vÎ²3 Receptors. Molecules, 2021, 26, 1792.	1.7	25
74	Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Research, 1999, 19, 1343-9.	0.5	25
75	Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with 68 Ga-DOTATOC PET. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 466-466.	3.3	24
76	Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. European Journal of Radiology, 2017, 96, 12-20.	1.2	24
77	Iterative Image Reconstruction for Clinical PET Using Ordered Subsets, Median Root Prior, and a Web-Based Interface. Molecular Imaging and Biology, 2002, 4, 219-231.	1.3	23
78	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics, 2018, 8, 76.	1.3	23
79	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	2.0	22
80	Fusion of Positron Emission Tomography (PET) and Gene Array Data: A New Approach for the Correlative Analysis of Molecular Biological and Clinical Data. IEEE Transactions on Medical Imaging, 2007, 26, 804-812.	5.4	21
81	The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. World Journal of Surgical Oncology, 2008, 6, 37.	0.8	21
82	Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography. Onkologie, 2008, 31, 107-112.	1.1	21
83	Evaluation of New Bone Formation in Normal and Osteoporotic Rats with a 3-mm Femur Defect: Functional Assessment with Dynamic PET-CT (dPET-CT) Using 2-Deoxy-2-[18F]Fluoro-d-glucose (18F-FDG) and 18F-Fluoride. Molecular Imaging and Biology, 2013, 15, 336-344.	1.3	21
84	Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. BioMed Research International, 2013, 2013, 1-7.	0.9	21
85	Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e389-e391.	1.3	21
86	Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. Journal of Nuclear Medicine, 2003, 44, 1933-9.	2.8	20
87	Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 573-583.	1.2	19
88	PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncology, 2015, 11, 1083-1091.	1.1	19
89	Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1573-1584.	3.3	18
90	Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules, 2020, 25, 134.	1.7	18

#	Article	IF	Citations
91	Calibration of cone beam CT using relative attenuation ratio for quantitative assessment of bone density: a small animal study. International Journal of Computer Assisted Radiology and Surgery, 2013, 8, 733-739.	1.7	17
92	Vemurafenib and ipilimumab: A promising combination? Results of a case series. OncoImmunology, 2016, 5, e1101207.	2.1	17
93	Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. EJNMMI Research, 2018, 8, 28.	1.1	17
94	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	3.3	17
95	PET-FDG as predictor of therapy response in patients with colorectal carcinoma. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2003, 47, 8-13.	0.5	17
96	Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. Journal of Nuclear Medicine, 2004, 45, 827-33.	2.8	15
97	Application of F-18-Sodium Fluoride (NaF) Dynamic PET-CT (dPET-CT) for Defect Healing: A Comparison of Biomaterials in an Experimental Osteoporotic Rat Model. Medical Science Monitor, 2014, 20, 1942-1949.	0.5	14
98	Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. Journal of Nuclear Medicine, 2006, 47, 1515-24.	2.8	14
99	Impact of Cell-Proliferation-Associated Gene Expression on 2-Deoxy-2-[18F]fluoro-d-Glucose (FDG) Kinetics as Measured by Dynamic Positron Emission Tomography (dPET) in Colorectal Tumors. Molecular Imaging and Biology, 2011, 13, 1290-1300.	1.3	13
100	Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1212-1223.	3.3	13
101	Preliminary evaluation of different biomaterials for defect healing in an experimental osteoporotic rat model with dynamic PET-CT (dPET-CT) using F-18-Sodium Fluoride (NaF). Injury, 2014, 45, 501-505.	0.7	13
102	Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Annals of Oncology, 2016, 27, 1353-1354.	0.6	13
103	Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images. Medical and Biological Engineering and Computing, 2005, 43, 23-32.	1.6	12
104	A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. BMC Cancer, 2011, 11, 510.	1.1	12
105	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis, 2019, 34, 239-244.	1.0	12
106	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). Annals of Surgical Oncology, 2019, 26, 1332-1339.	0.7	12
107	Quantitative dynamic ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica, 2019, 104, e420-e423.	1.7	12
108	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers, 2021, 13, 1019.	1.7	12

#	Article	IF	Citations
109	Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. EJNMMI Research, 2011, 1, 34.	1.1	11
110	Dynamic PET With FDG in Patients With Unresectable Aggressive Fibromatosis. Clinical Nuclear Medicine, 2012, 37, 943-948.	0.7	11
111	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. Cancers, 2019, 11, 790.	1.7	11
112	Parametric imaging: a promising approach for the evaluation of dynamic PET-18F-FDG studies - the DKFZ experience. Hellenic Journal of Nuclear Medicine, 2010, 13, 18-22.	0.2	11
113	The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin. Marine Drugs, 2009, 7, 331-340.	2.2	10
114	MRâ€“Consistent Simultaneous Reconstruction of Attenuation and Activity for Nonâ€“TOF PET/MR. IEEE Transactions on Nuclear Science, 2016, 63, 2443-2451.	1.2	10
115	Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. Cancers, 2021, 13, 586.	1.7	10
116	Parametric Imaging With Dynamic PET for Oncological Applications: Protocols, Interpretation, Current Applications and Limitations for Clinical Use. Seminars in Nuclear Medicine, 2022, 52, 312-329.	2.5	10
117	Transfer of the sFLT-1 Gene in Morris Hepatoma Results in Decreased Growth and Perfusion and Induction of Genes Associated with Stress Response. Clinical Cancer Research, 2005, 11, 2132-2140.	3.2	9
118	Integrated telemedicine applications and services for oncological positron emission tomography. Oncology Reports, 2006, 15, 1091-1100.	1.2	9
119	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open, 2016, 6, e009558.	0.8	9
120	Positron Emission Tomography in Merkel Cell Carcinoma. Cancers, 2020, 12, 2897.	1.7	9
121	Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers. Medical Science Monitor, 2013, 19, 875-882.	0.5	9
122	Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2011-2023.	3.3	8
123	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	1.7	8
124	Correlation of Dynamic PET and Gene Array Data in Patients with Gastrointestinal Stromal Tumors. Scientific World Journal, The, 2012, 2012, 1-5.	0.8	7
125	18F-FDG PET in a 10-year-old female patient with subacute sclerosing panencephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1100-1101.	3.3	6
126	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. Cancers, 2020, 12, 1335.	1.7	6

#	Article	IF	Citations
127	Immuno-Imaging (PET/SPECT)â€“Quo Vadis?. Molecules, 2022, 27, 3354.	1.7	6
128	Can PETâ€“CT with FDG replace contrast enhanced CT for imaging of liver metastases?. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1902-1905.	3.3	5
129	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clinical Nuclear Medicine, 2016, 41, 156-158.	0.7	5
130	Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1226-1234.	3.3	4
131	Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI. Diagnostics, 2019, 9, 179.	1.3	4
132	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers, 2020, 12, 3004.	1.7	3
133	Positron Emission Tomography (PET) and Macromolecular Delivery In Vivo. Methods in Molecular Biology, 2009, 480, 187-198.	0.4	2
134	Making sense of the biological complexity through the platform-driven unification of the analytical and visualization tasks. , 2015, , .		2
135	Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. Diagnostics, 2021, 11, 649.	1.3	2
136	Predicting Therapy Outcome with Quantitative PET: What Is Needed and What Can Be Done?. Onkologie, 2009, 32, 706-707.	1.1	1
137	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. Clinical and Translational Imaging, 2014, 2, 33-41.	1.1	1
138	Comparison of functional imaging in multiple myeloma patients: Indication for hybrid-imaging with PET/MRI?. Cancer Imaging, 2015, 15, .	1.2	1
139	Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Diagnostics, 2017, 7, 61.	1.3	1
140	Diet-dependent toxicity of ipilimumab in metastatic melanoma. European Journal of Cancer, 2019, 106, 220-224.	1.3	1
141	Vemurafenib and ipilimumab: A promising combination?. Journal of Clinical Oncology, 2015, 33, e20075-e20075.	0.8	1
142	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. Cancers, 2021, 13, 5170.	1.7	1
143	Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. Blood, 2018, 132, 3180-3180.	0.6	1
144	European health telematics networks for positron emission tomography. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 626-630.	0.7	0

#	Article	IF	Citations
145	Positron Emission Tomography (PET) Applications. , 2010, , 2247-2252.		0
146	Reply: Comment on: â€œTumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic ¹⁸F-FDG PET/CTâ€• Journal of Nuclear Medicine, 2014, 55, 351-352.	2.8	0
147	Positron Emission Tomography (PET) Applications. , 2017, , 718-722.		0